Analysts expect that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will announce sales of $1.37 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Adamas Pharmaceuticals’ earnings, with estimates ranging from $1.25 million to $1.50 million. The company is scheduled to issue its next earnings results on Tuesday, May 8th.
On average, analysts expect that Adamas Pharmaceuticals will report full-year sales of $1.37 million for the current fiscal year, with estimates ranging from $21.70 million to $26.65 million. For the next financial year, analysts forecast that the company will report sales of $82.39 million per share, with estimates ranging from $75.00 million to $89.78 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.09). The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.84 million. The business’s quarterly revenue was up 1435.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.68) EPS.
A number of equities analysts have recently weighed in on ADMS shares. Cowen set a $55.00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 13th. Northland Securities started coverage on Adamas Pharmaceuticals in a report on Wednesday, November 29th. They issued an “outperform” rating for the company. Mizuho reissued a “buy” rating and issued a $48.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, January 23rd. BidaskClub cut Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 3rd. Finally, William Blair reissued an “outperform” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, February 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $45.14.
Adamas Pharmaceuticals stock traded down $1.25 on Friday, reaching $25.85. The company’s stock had a trading volume of 466,573 shares, compared to its average volume of 1,121,131. The company has a debt-to-equity ratio of 1.55, a quick ratio of 10.69 and a current ratio of 10.79. The stock has a market capitalization of $726.48, a P/E ratio of -6.84 and a beta of 1.59. Adamas Pharmaceuticals has a one year low of $13.50 and a one year high of $44.00.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Adamas Pharmaceuticals in the third quarter worth $110,000. Quantbot Technologies LP acquired a new position in Adamas Pharmaceuticals in the third quarter valued at $119,000. Sei Investments Co. increased its stake in Adamas Pharmaceuticals by 1,105.0% in the third quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock valued at $185,000 after purchasing an additional 8,033 shares during the last quarter. Granite Springs Asset Management LLC acquired a new position in Adamas Pharmaceuticals in the fourth quarter valued at $207,000. Finally, FNY Partners Fund LP acquired a new position in Adamas Pharmaceuticals in the third quarter valued at $231,000. 77.25% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://ledgergazette.com/2018/03/19/zacks-analysts-anticipate-adamas-pharmaceuticals-inc-adms-will-post-quarterly-sales-of-1-37-million.html.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.